Search hospitals > Kansas > Wichita
Cancer Center of Kansas - Wichita
Claim this profileWichita, Kansas 67214
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
574 reported clinical trials
4 medical researchers
Summary
Cancer Center of Kansas - Wichita is a medical facility located in Wichita, Kansas. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Cancer Center of Kansas - Wichita is involved with conducting 574 clinical trials across 522 conditions. There are 4 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Dennis F. Moore, Shaker Dahkil, MD, and Bassam I. Mattar, MD.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Shaker Dakhil, M.D.Ascension Via Christi Hospitals Wichita6 years of reported clinical research
Expert in Breast Cancer
Expert in Lung Cancer
83 reported clinical trials
170 drugs studied
Dennis F. MooreAscension Via Christi Hospitals Wichita4 years of reported clinical research
Studies Lung Cancer
Studies Breast Cancer
30 reported clinical trials
80 drugs studied
Shaker Dahkil, MDCancer Center of Kansas5 years of reported clinical research
Studies Renal Cell Carcinoma
Studies Breast Cancer
1 reported clinical trial
4 drugs studied
Bassam I. Mattar, MDCancer Center of Kansas4 years of reported clinical research
Studies Mixed-Cell Lymphoma
Studies Lymphoma
1 reported clinical trial
2 drugs studied
Clinical Trials running at Cancer Center of Kansas - Wichita
Breast Cancer
Lung Cancer
Esophageal cancer
Bladder Cancer
Bladder Carcinoma
Breast cancer
Cancer
Gastric cancer
Kidney Cancer
Non-Small Cell Lung Cancer
HER2-Targeted Therapy
for Breast Cancer
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.
Recruiting2 awards Phase 35 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cancer Center of Kansas - Wichita?
Cancer Center of Kansas - Wichita is a medical facility located in Wichita, Kansas. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Cancer Center of Kansas - Wichita is involved with conducting 574 clinical trials across 522 conditions. There are 4 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Dennis F. Moore, Shaker Dahkil, MD, and Bassam I. Mattar, MD.
Where is Cancer Center of Kansas - Wichita located?
The Cancer Center of Kansas is located at 818 N. Emporia, Suite 403, Wichita, KS 67214, with multiple locations throughout Wichita.
Who should I call to ask about financial aid or insurance network?
The Cancer Center of Kansas complies with Federal civil rights laws, ensuring no discrimination based on race, color, national origin, age, disability, or sex. For general inquiries, please call 316-262-4467. For financial assistance related to medical bills, contact the University of Kansas Health System at 913-588-5820.
What insurance does Cancer Center of Kansas - Wichita accept?
The Cancer Center of Kansas - Wichita accepts a wide range of insurance plans, including commercial insurance, Medicare, Medicare Part C, Medicaid, U.S. Department of Veterans Affairs, and TRICARE plans. For specific coverage details, it is recommended to contact an Oncology Information Specialist at the hospital or Outpatient Care Center.
What awards or recognition has Cancer Center of Kansas - Wichita received?
The Cancer Center of Kansas in Wichita, Kansas, is a distinguished recipient of the 2018 and 2016 Favorite for Best Hospital for Cancer Care in Wichita Kansas Reader's Choice Awards. It was also named the 2016 Employer of the Year by CLASS LTD for its commitment to employing individuals with intellectual or other developmental disabilities. Furthermore, the center earned recognition as a 2016 Admirable Statewide Partner for its outstanding dedication.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.